Mary Caffrey

Selected coverage of myelodysplastic syndromes and myeloproliferative disease at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of multiple myeloma from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Selected coverage of classical Hodgkin lymphoma (cHL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of mantle cell lymphoma (MCL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer.

The PD-1 inhibitor is being studied in multiple cancers; FDA is reviewing an application of a combination with rivoceranib in unresectable hepatocellular carcinoma.

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

Shifting from an opt-in to an opt-out approach boosted palliative care consults from 16.6% of eligible patients to 43.9%, the investigators found.

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.

Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.

Articles highlighting links between COVID-19 and cancer were among the most-read in Evidence-Based Oncology™ in 2023.

An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention.

Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).

The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California.

Robert Rifkin, MD, medical oncologist and hematologist at Rocky Mountain Cancer Centers, shares insight into how the phase 2 Optec study of teclistamab administration in the outpatient setting could help achieve important health equity and quality goals.

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center, presented phase 2 results for 25 patients with TP53 mutations.

Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).

Minimal residual disease (MRD) is not accepted by regulators as a surrogate end point, but a commenter at the American Society of Hematology plenary session said one is needed.